Sector
PharmaceuticalsOpen
₹18.8Prev. Close
₹18.87Turnover(Lac.)
₹0.68Day's High
₹19.43Day's Low
₹18.0252 Week's High
₹2952 Week's Low
₹13.11Book Value
₹6.65Face Value
₹10Mkt Cap (₹ Cr.)
27.35P/E
28.16EPS
0.67Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 14.18 | 4.88 | 4.88 | 4.88 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.64 | -5.72 | -5.76 | -5.77 |
Net Worth | 8.54 | -0.84 | -0.88 | -0.89 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 0.01 | 0 | 0 | 1.56 |
yoy growth (%) | 0 | 0 | -100 | 9,330.96 |
Raw materials | 0 | 0 | 0 | -1.5 |
As % of sales | 77.22 | 0 | 0 | 96.22 |
Employee costs | 0 | -0.01 | -0.02 | -0.03 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -0.1 | 0 | -0.01 | 0 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 6.4 |
Working capital | 0 | -0.01 | 0.01 | 0.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | -100 | 9,330.96 |
Op profit growth | 457.54 | -70.39 | -791.1 | 1,587.44 |
EBIT growth | 1,944.45 | -69.78 | -271.28 | 1,587.44 |
Net profit growth | 1,944.45 | -69.78 | -270.19 | -99.56 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director & CFO
Murli Shivshankaran Nair
Non Executive Director
Reena Mahatma
Independent Director
Narayansinh Padudansinh Chauhan
Independent Director
Gautam Keshavlal Chauhan
Company Sec. & Compli. Officer
Manmeetkaur Harshdeepsingh Bhatia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gujarat Inject (Kerala) Ltd
Summary
Gujarat Inject Kerala Limited was incorporated in Jan. 91. In 2004-05, Company started production of I.V. FIuids in April, 2005.
Read More
The Gujarat Inject Kerala Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹18.67 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Inject Kerala Ltd is ₹27.35 Cr. as of 09 May ‘25
The PE and PB ratios of Gujarat Inject Kerala Ltd is 28.16 and 2.84 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Gujarat Inject Kerala Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gujarat Inject Kerala Ltd is ₹13.11 and ₹29 as of 09 May ‘25
Gujarat Inject Kerala Ltd's CAGR for 5 Years at N/I%, 3 Years at 98.03%, 1 Year at 19.05%, 6 Month at 3.11%, 3 Month at -32.82% and 1 Month at -27.51%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.